# A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

> **NCT04962503** · PHASE2 · COMPLETED · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 6 (actual)

## Conditions studied

- Arterial Ischemic Stroke

## Interventions

- **DRUG:** Afamelanotide

## Key facts

- **NCT ID:** NCT04962503
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-03
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-02-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04962503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04962503, "A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04962503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*